Market Overview

Synageva Announces $80M Proposed Offering of Common Stock


Synageva BioPharma Corp. (“Synageva”) (NASDAQ: GEVA), a clinical
stage biopharmaceutical company developing therapeutic products for rare
disorders, today announced that it has commenced a $80 million
underwritten public offering of shares of its common stock. In
connection with this offering, Synageva expects to grant to the
underwriters a 30-day option to purchase additional shares of common
stock, equal to up to 15% of the number of shares of common stock sold
in the offering. Morgan Stanley and J.P. Morgan are acting as joint
book-running managers in the offering, and Cowen and Company is acting
as co-manager in the offering.

The securities described above are being offered by Synageva pursuant to
a Form S-3 shelf registration

See full press release

Posted-In: News Guidance


Related Articles (GEVA)

View Comments and Join the Discussion!

Partner Center